Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Revelation Biosciences Inc (REVB)

Revelation Biosciences Inc (REVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,576
  • Shares Outstanding, K 3,720
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,910 K
  • EBIT $ -9 M
  • EBITDA $ -9 M
  • 60-Month Beta -0.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.93

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.15
  • Number of Estimates 2
  • High Estimate $-0.75
  • Low Estimate $-1.55
  • Prior Year $-25.32
  • Growth Rate Est. (year over year) +95.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0600 +17.92%
on 03/30/26
1.4276 -12.44%
on 03/11/26
-0.0400 (-3.10%)
since 03/02/26
3-Month
1.0600 +17.92%
on 03/30/26
5.8000 -78.45%
on 01/23/26
-2.0028 (-61.57%)
since 01/02/26
52-Week
1.0600 +17.92%
on 03/30/26
44.7696 -97.21%
on 04/08/25
-30.7900 (-96.10%)
since 04/02/25

Most Recent Stories

More News
Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study

- A majority of CKD patients present with cellular inflammation and immunoparalysis predose -

REVB : 1.2500 (+1.63%)
REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation...

REVB : 1.2500 (+1.63%)
Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

SAN DIEGO, CA / ACCESS Newswire / March 19, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation...

REVB : 1.2500 (+1.63%)
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025

SAN DIEGO, CA / ACCESS Newswire / February 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation...

REVB : 1.2500 (+1.63%)
Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026

SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announced today that, on January 28, 2026, the Company will implement...

REVB : 1.2500 (+1.63%)
Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds

SAN DIEGO, CA / ACCESS Newswire / January 23, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation,...

REVB : 1.2500 (+1.63%)
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)

- Presentation to Include Additional Positive Data from the Recently Completed PRIME Clinical Study -

REVB : 1.2500 (+1.63%)
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, CA / ACCESS Newswire / January 12, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation,...

REVB : 1.2500 (+1.63%)
Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development

SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation,...

REVB : 1.2500 (+1.63%)

Business Summary

Revelation Biosciences Inc. is a clinical-stage life sciences company. It focused on the development of immunologic-based therapies for the prevention and treatment of disease. The company's product pipeline includes REVTx-99, REVTx-200 and REVDx-501. Revelation Biosciences Inc., formerly known as Petra...

See More

Key Turning Points

3rd Resistance Point 1.3167
2nd Resistance Point 1.2833
1st Resistance Point 1.2667
Last Price 1.2500
1st Support Level 1.2167
2nd Support Level 1.1833
3rd Support Level 1.1667

See More

52-Week High 44.7696
Fibonacci 61.8% 28.0725
Fibonacci 50% 22.9148
Fibonacci 38.2% 17.7571
Last Price 1.2500
52-Week Low 1.0600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.